EMA Authorised: Deferasirox Mylan (deferasirox) — Mylan Pharmaceuticals Limited

View source ↗

Summary

EMA has authorised Deferasirox Mylan (deferasirox) for treatment of iron overload, including in patients with beta-thalassemia. This marks EU approval of a gene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Iron Overload

Drugs mentioned

• Deferasirox Mylan (deferasirox)

Snippet

Status: Authorised. Therapeutic area: Iron Overload;beta-Thalassemia. MAH: Mylan Pharmaceuticals Limited. Decision date: 30/04/2025